SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
DATE OF REPORT: MAY 22, 2002
(Date of earliest event reported)
GENOMIC SOLUTIONS INC.
(Exact name of registrant as specified in its charter)
DELAWARE COMMISSION FILE NO. 000-30549 38-3383038
(State of incorporation) (IRS Employer I.D. No.)
4355 VARSITY DRIVE
ANN ARBOR, MICHIGAN 48108
(Address of principal executive offices)
(734) 975-4800
(Registrant's telephone number, including area code)
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
On May 22, 2002, the Board of Directors of Genomic Solutions Inc. ("the
Company") and its Audit Committee dismissed Arthur Andersen LLP ("Arthur
Andersen" or "Andersen") as the Company's independent public accountants and
engaged Ernst & Young ("E&Y") to serve as the Company's independent public
accountants for the fiscal year 2002.
Arthur Andersen's reports on the Company's consolidated financial
statements for the years ended 2001 and 2000 did not contain an adverse opinion
or disclaimer of opinion, nor were they qualified or modified as to uncertainty,
audit scope or accounting principles.
During the years ended December 31, 2001 and 2000 and through May 22,
2002, there were no disagreements with Andersen on any matter of accounting
principle or practice, financial statement disclosure, or auditing scope or
procedure which, if not resolved to Andersen's satisfaction, would have caused
them to make reference to the subject matter in connection with their report on
the Company's consolidated financial statements for such years; and there were
no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.
The Company provided Andersen with a copy of the foregoing disclosures.
Attached as Exhibit 16 is a copy of Andersen's letter, dated May 22, 2002,
stating its agreement with such statements.
During the years ended December 31, 2001 and 2000 and through the date
of the Board's decision, the Company did not consult E&Y with respect to the
application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered on
the Company's consolidated financial statements, or any other matters or
reportable events as set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.
ITEM 7. EXHIBITS
16. Letter from Arthur Andersen LLP to the Securities and Exchange
Commission, dated May 22, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOMIC SOLUTIONS INC.,
a Delaware corporation
Date: May 22, 2002 By: /s/ Steven J. Richvalsky
---------------------------
Steven J. Richvalsky
Its: Executive Vice President
and Chief Financial Officer
Exhibit Index
Exh. NO Description
- ------- -----------
16. Letter from Arthur Andersen LLP to the Securities and Exchange
Commission, dated May 22, 2002.